Results 81 to 90 of about 72,405 (280)

Infliximab for the treatment of plaque psoriasis

open access: yes, 2008
Jennifer S Gall, Robert E KalbState University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USAAbstract: Infliximab is a monoclonal antibody that targets tumor necrosis factor-α (TNF& ...
Jennifer S Gall, Robert E Kalb
core  

Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review

open access: yes, 2015
The efficacy of infliximab is influenced by individual variability in its pharmacokinetics and pharmacodynamics. Serum infliximab concentrations could therefore be related to the efficacy and tolerance of infliximab, and assist adjustment of treatment ...
Machet, Laurent   +5 more
core   +1 more source

Chronic conditions associated with paediatric onset inflammatory bowel diseases: A population‐based study

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective Several conditions are associated with inflammatory bowel disease (IBD), including immune‐mediated inflammatory diseases (IMIDs), extraintestinal manifestations (EIMs), and psychiatric disorders. This study aimed to describe at population‐level the comorbidities and their relative burden in paediatric‐onset IBD (pIBD).
Nicolas Richard   +480 more
wiley   +1 more source

Infliximab in the treatment of plaque type psoriasis

open access: yes, 2009
Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio ChimentiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, ItalyAbstract: Psoriasis is a chronic and immunomediated skin disease characterized by ...
Andrea Saggini   +3 more
core  

Fecal microRNA signatures as non‐invasive diagnostic and prognostic markers of pediatric inflammatory bowel diseases

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives The identification of novel noninvasive diagnostic and prognostic biomarkers for pediatric inflammatory bowel disease (PIBD), including pediatric Crohn's disease (pCD) and ulcerative colitis (pUC), is crucial for improving therapeutic outcomes.
Tereza Pinkasova   +11 more
wiley   +1 more source

Efficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition ...
Luca Scarallo   +45 more
wiley   +1 more source

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)

open access: yes, 2019
Farhad Salehzadeh,1 Yusef Mohammadikebar,2 Afsaneh Enteshary,2 Omid Ghanbarpour,1 Mehrdad Mirzarahimi11Department of Pediatric, Bouali Children’s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran; 2Department of Internal ...
Salehzadeh F   +4 more
core  

Infliximab in Crohn's disease-associated toxic megacolon

open access: yes, 2012
Item does not contain fulltextRefractory medical treatment of Crohn disease-associated toxic megacolon usually requires surgery, which carries substantial morbidity and mortality.
Geenen, E.J.M. van   +3 more
core   +1 more source

Real‐world paediatric inflammatory bowel disease surgery: International variation in care and practice

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective Paediatric inflammatory bowel disease (IBD) surgery is delivered across heterogeneous settings, with limited paediatric‐specific evidence guiding organisation of care, perioperative management, and operative strategy. We characterised contemporary international practice.
Vojtech Dotlacil   +24 more
wiley   +1 more source

Higher incidence of paediatric autoimmune liver disease post‐COVID

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives A higher incidence of autoimmune conditions with greater disease severity is reported post‐Coronavirus Disease (COVID). The incidence and disease severity of paediatric autoimmune liver disease (AILD) post‐COVID has not been assessed.
Suz Warner   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy